ATLANTA, GA – – (Globe Newswire – October 27, 2026) – – A shareholder class action lawsuit has been filed against Tenax Therapeutics, Inc. (“Tenax”) (NASDAQ: TENX). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) TNX-103 was less effective than Defendants had led investors to believe; (ii) accordingly, TNX-103’s overall clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Tenax’s public statements were materially false and misleading at all relevant times.

If you purchased Tenax shares between November 13, 2023 and August 7, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/tenax-therapeutics/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is December 28, 2026.